Sharp Brains: Brain Fitness and Cognitive Health News

Neuroplasticity, Brain Fitness and Cognitive Health News


Study: Common medication treatments for PTSD can increase the risk of developing dementia


Drugs for PTSD linked to increased risk of demen­tia (The Phar­ma­ceu­ti­cal Jour­nal):

Cer­tain psy­chotrop­ic drugs used to treat post-trau­mat­ic stress dis­or­der (PTSD) increase the risk of devel­op­ing demen­tia, includ­ing in patients who do not have PTSD but take the drugs for oth­er con­di­tions, study results pub­lished in the Jour­nal of the Amer­i­can Geri­atrics Soci­ety

As expect­ed, a diag­no­sis of PTSD was found to sig­nif­i­cant­ly increase the risk of a demen­tia diagnosis…the results show that the use of selec­tive sero­tonin reup­take inhibitors, nov­el anti­de­pres­sants and atyp­i­cal antipsy­chotics increased that risk of demen­tia still fur­ther… Vet­er­ans who did not have PTSD and took the drugs also had an increased risk of demen­tia.

While the use of sero­tonin-nor­ep­i­neph­rine reup­take inhibitors (SNRI) or ben­zo­di­azepines (BZA) to treat PTSD was not found to sig­nif­i­cant­ly increase the risk of demen­tia specif­i­cal­ly in patients with PTSD, the results showed that use of either drug was found to be inde­pen­dent­ly asso­ci­at­ed with an increased risk of demen­tia diag­no­sis in the vet­er­ans, regard­less of PTSD diag­no­sis.”

The Study

PTSD, Psy­chotrop­ic Med­ica­tion Use, and the Risk of Demen­tia Among US Vet­er­ans: A Ret­ro­spec­tive Cohort Study (Jour­nal of the Amer­i­can Geri­atrics Soci­ety). From the abstract:

  • Objec­tive: To deter­mine the asso­ci­a­tions between PTSD, psy­chotrop­ic med­ica­tion use, and the risk for demen­tia.
  • Results: PTSD diag­no­sis sig­nif­i­cant­ly increased the risk for demen­tia diag­no­sis (HR = 1.35; [95% CI = 1.27–1.43]). How­ev­er, there were sig­nif­i­cant inter­ac­tions between PTSD diag­no­sis and use of SSRIs (P < .001), NAs (P = .014), and AAs (P < .001) on the risk for demen­tia diag­no­sis. HR for demen­tia diag­no­sis among vet­er­ans diag­nosed with PTSD and not using psy­chotrop­ic med­ica­tions was 1.55 [1.45–1.67]. Among vet­er­ans diag­nosed with PTSD pre­scribed SSRI, SNRI, or AA, HR for demen­tia diag­no­sis var­ied by drug class use rang­ing from 1.99 for SSRI to 4.21 for AA, rel­a­tive to vet­er­ans with­out a PTSD diag­no­sis and no psy­chotrop­ic med­ica­tion receipt. BZAs or SNRIs use at base­line was asso­ci­at­ed with a sig­nif­i­cant­ly increased risk for demen­tia diag­no­sis inde­pen­dent of a PTSD diag­no­sis.
  • Con­clu­sion: PTSD diag­no­sis is asso­ci­at­ed with an increased risk for demen­tia diag­no­sis that var­ied with receipt of psy­chotrop­ic med­ica­tions. Fur­ther research would help to delin­eate if these find­ings are due to dif­fer­ences in PTSD sever­i­ty, psy­chi­atric comor­bid­i­ty, or inde­pen­dent effects of psy­chotrop­ic med­ica­tions on cog­ni­tive decline.

To Learn More

Leave a Reply...

Loading Facebook Comments ...

Leave a Reply

Categories: Cognitive Neuroscience, Health & Wellness

Tags: , , , , , , , , , , , , ,

All Slidedecks & Recordings Available — click image below

Search for anything brain-related in our article archives

About SharpBrains

As seen in The New York Times, The Wall Street Journal, BBC News, CNN, Reuters, and more, SharpBrains is an independent market research firm and think tank tracking health and performance applications of brain science.